Company / Current Assets
UroGen Pharma Ltd. Current Assets History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$186.0M
FY2025
5-year range
$114.4M / $276.1M
FY2021-FY2025
Trend
-32.6%
vs FY2024
Sector context
#192 of 213
Health Care
What the data says
Among 213 Health Care companies, UroGen Pharma Ltd. is in the bottom 10% for current assets. Current Assets has fluctuated over the past 9 years, ranging from $74M in FY2017 to $276M in FY2024.
Based on SEC 10-K filings.
$186M in FY2025 with a 5-year CAGR of +10.0%.
Improved from $169M to $186M over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +13.0%
- 5-Year CAGR
- +10.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 213This company $186.0M Sector average $2.5B
▼
-92.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.0%, indicating consistent growth.
- In FY2025, current assets decreased 32.6% year-over-year.
- Ranks #192 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $186.0M | -32.6% |
| FY2024 | $276.1M | +63.2% |
| FY2023 | $169.2M | +31.2% |
| FY2022 | $128.9M | +12.7% |
| FY2021 | $114.4M | -1.1% |
| FY2020 | $115.6M | -22.2% |
| FY2019 | $148.6M | +45.4% |
| FY2018 | $102.2M | +37.3% |
| FY2017 | $74.5M | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026